

54. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA protein so bound comprises amino acid residues 1 through 123 as described in SEQ ID NO:2. --
55. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 2 through 50 as described in SEQ ID NO:2. --
56. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 85 through 123 as described in SEQ ID NO:2. --
57. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 46 through 109 as described in SEQ ID NO:2. --
58. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 18 through 98 as described in SEQ ID NO:2. --
59. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 22 through 99 as described in SEQ ID NO:2. --
60. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 21 through 50 as described in SEQ ID NO:2. --
61. (NEW) The anti-idiotypic antibody of claim 53 wherein the PSCA so bound comprises amino acid residues 46 through 85 as described in SEQ ID NO:2. --
62. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound by the antibody which binds to a Prostate Stem Cell Antigen (PSCA) comprises amino acid residues 50 through 64 as described in SEQ ID NO:2. --

63. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 67 through 81 as described in SEQ ID NO:2. --
64. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 21 through 99 as described in SEQ ID NO:2. --
65. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 71 through 82 as described in SEQ ID NO:2. --
66. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 85 through 99 as described in SEQ ID NO:2. --
67. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 18 through 50 as described in SEQ ID NO:2. --
68. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 46 through 98 as described in SEQ ID NO:2. --
69. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 85 through 98 as described in SEQ ID NO:2. --
70. (NEW) A method for inducing an immune response in a subject, comprising administering to the subject the anti-idiotypic PSCA antibody of claim 53. --
71. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 1 through 123 of PSCA as described in SEQ ID NO:2. --

- 72. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 2 through 50 of PSCA as described in SEQ ID NO:2. --
- 73. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 85 through 123 of PSCA as described in SEQ ID NO:2. --
- 74. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 46 through 109 of PSCA as described in SEQ ID NO:2. --
- 75. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 18 through 98 of PSCA as described in SEQ ID NO:2. --
- 76. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 22 through 99 of PSCA as described in SEQ ID NO:2. --
- 77. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 21 through 50 of PSCA as described in SEQ ID NO:2. --
- 78. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 46 through 85 of PSCA as described in SEQ ID NO:2. --

- 79. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 50 through 64 of PSCA as described in SEQ ID NO:2. --
- 80. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 67 through 81 of PSCA as described in SEQ ID NO:2. --
- 81. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 21 through 99 of PSCA as described in SEQ ID NO:2. --
- 82. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 71 through 82 of PSCA as described in SEQ ID NO:2. --
- 83. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 85 through 99 of PSCA as described in SEQ ID NO:2. --
- 84. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 18 through 50 of PSCA as described in SEQ ID NO:2. --
- 85. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 46 through 98 of PSCA as described in SEQ ID NO:2. --